Teresa Morán

18.7k total citations
130 papers, 2.7k citations indexed

About

Teresa Morán is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Teresa Morán has authored 130 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Pulmonary and Respiratory Medicine, 82 papers in Oncology and 45 papers in Molecular Biology. Recurrent topics in Teresa Morán's work include Lung Cancer Treatments and Mutations (83 papers), Lung Cancer Research Studies (37 papers) and Cancer Genomics and Diagnostics (30 papers). Teresa Morán is often cited by papers focused on Lung Cancer Treatments and Mutations (83 papers), Lung Cancer Research Studies (37 papers) and Cancer Genomics and Diagnostics (30 papers). Teresa Morán collaborates with scholars based in Spain, United States and France. Teresa Morán's co-authors include Rafael Rosell, Bartomeu Massutí, Miquel Tarón, Noemı́ Reguart, Enric Carcereny, Dolores Isla, Margarita Majem, José Javier Sánchez, Cristina Queralt and Miguel Ángel Molina‐Vila and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Teresa Morán

126 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Teresa Morán Spain	26	1.9k	1.6k	1.0k	627	177	130	2.7k
Roberta Minari Italy	25	1.7k 0.9×	1.5k 0.9×	1.1k 1.1×	585 0.9×	208 1.2×	66	2.5k
Shang‐Gin Wu Taiwan	29	1.9k 1.0×	1.5k 0.9×	955 0.9×	683 1.1×	160 0.9×	64	2.6k
C. Anger United Kingdom	3	2.6k 1.4×	2.3k 1.5×	945 0.9×	471 0.8×	153 0.9×	10	3.3k
Atsushi Horiike Japan	28	1.3k 0.7×	1.3k 0.8×	604 0.6×	391 0.6×	152 0.9×	107	2.1k
Annetta Krebs United States	8	1.9k 1.0×	2.0k 1.2×	723 0.7×	395 0.6×	163 0.9×	8	2.8k
Kenji Tomizawa Japan	26	1.5k 0.8×	1.3k 0.8×	874 0.8×	393 0.6×	142 0.8×	72	2.4k
Riyaz Shah United Kingdom	19	3.3k 1.8×	2.8k 1.7×	1.1k 1.1×	708 1.1×	183 1.0×	48	3.9k
Jean-Claude Cutz Canada	9	1.8k 1.0×	1.6k 1.0×	815 0.8×	519 0.8×	129 0.7×	12	2.4k
Xian Lu United States	20	1.3k 0.7×	1.1k 0.7×	642 0.6×	454 0.7×	131 0.7×	39	1.9k
Amrita Desai United States	19	1.1k 0.6×	1.3k 0.8×	657 0.6×	359 0.6×	274 1.5×	36	2.3k

Countries citing papers authored by Teresa Morán

Since Specialization

Citations

This map shows the geographic impact of Teresa Morán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teresa Morán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teresa Morán more than expected).

Fields of papers citing papers by Teresa Morán

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teresa Morán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teresa Morán. The network helps show where Teresa Morán may publish in the future.

Co-authorship network of co-authors of Teresa Morán

This figure shows the co-authorship network connecting the top 25 collaborators of Teresa Morán. A scholar is included among the top collaborators of Teresa Morán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teresa Morán. Teresa Morán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

González‐Cao, María, Xueting Cai, Jillian Wilhelmina Paulina Bracht, et al.. (2024). HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer. PubMed. Volume 15. 55–67. 3 indexed citations

Bosch‐Barrera, Joaquim, Teresa Morán, Purificación Estévez-García, et al.. (2023). Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.. Journal of Clinical Oncology. 41(16_suppl). 9059–9059. 1 indexed citations

Carbonell, Caterina, Joan Frigola, Núria Pardo, et al.. (2023). Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. Molecular Oncology. 17(5). 779–791. 4 indexed citations

Postel‐Vinay, Sophie, Matthieu Texier, Mihaela Aldea, et al.. (2023). Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British Journal of Cancer. 130(3). 417–424. 4 indexed citations

Carcereny, Enric, Maria Saigí, Anna Esteve, et al.. (2023). P1.21-04 Role of HLA-I as a Molecular Prognostic Factor for Long Term Responders in Non-small Cell Lung Cancer Patients Treated with Immunotherapy. Journal of Thoracic Oncology. 18(11). S235–S235. 1 indexed citations

Camidge, D. Ross, Teresa Morán, Ingel Demedts, et al.. (2022). A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. Clinical Lung Cancer. 23(4). 300–310. 19 indexed citations

Odeny, Thomas, Kathryn Lurain, Julius Strauss, et al.. (2022). Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. Journal for ImmunoTherapy of Cancer. 10(9). e005128–e005128. 7 indexed citations

Hernández, Ainhoa, Eudald Felip, Marc Cucurull, et al.. (2022). Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer—COVID Lung Vaccine Study. Cancers. 15(1). 137–137. 4 indexed citations

Bosch‐Barrera, Joaquim, Sara Verdura, J.C. Ruffinelli, et al.. (2021). Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers. 13(16). 4168–4168. 11 indexed citations

10.

Garrido, Pilar, Luis Paz‐Ares, Margarita Majem, et al.. (2021). LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 10(17). 5878–5888. 14 indexed citations

11.

Dómine, Manuel, Teresa Morán, Dolores Isla, et al.. (2020). SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clinical & Translational Oncology. 22(2). 245–255. 40 indexed citations

12.

Cirauqui, Beatriz, Teresa Morán, Anna Estival, et al.. (2020). Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management. Case Reports in Oncology. 13(1). 130–138. 2 indexed citations

13.

Martínez‐Morillo, Melania, et al.. (2020). IgA vasculitis and polymyalgia rheumatica induced by durvalumab. Translational Lung Cancer Research. 9(2). 421–423. 8 indexed citations

14.

Morán, Teresa, Vanesa Quiroga, Beatriz Cirauqui, et al.. (2019). A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and <b><i>EGFR</i></b>-Mutant Non-Small Cell Lung Cancer. Oncology Research and Treatment. 42(3). 107–114. 6 indexed citations

15.

Sanz‐Santos, José, Pere Serra, Felipe Andreo, et al.. (2017). Transbronchial and transesophageal fine-needle aspiration using a single ultrasound bronchoscope in the diagnosis of locoregional recurrence of surgically-treated lung cancer. BMC Pulmonary Medicine. 17(1). 46–46. 12 indexed citations

16.

Grève, Jacques De, Teresa Morán, Marie-Pascale Graas, et al.. (2015). Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer. 88(1). 63–69. 69 indexed citations

17.

Costa, Carlota, Miguel Angel Molina, Ana Drozdowskyj, et al.. (2014). The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research. 20(7). 2001–2010. 180 indexed citations

18.

Molina‐Vila, Miguel Ángel, Jordi Bertrán-Alamillo, Amaya Gascó, et al.. (2014). Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 20(17). 4647–4659. 125 indexed citations

19.

Reguart, Noemı́, Rafael Rosell, Felipe Cardenal, et al.. (2014). Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer. 84(2). 161–167. 72 indexed citations

20.

Simonetti, S., Miguel Ángel Molina‐Vila, Cristina Queralt, et al.. (2010). Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. Journal of Translational Medicine. 8(1). 135–135. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact